Correlation Between Passage Bio and Akero Therapeutics

Can any of the company-specific risk be diversified away by investing in both Passage Bio and Akero Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Passage Bio and Akero Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Passage Bio and Akero Therapeutics, you can compare the effects of market volatilities on Passage Bio and Akero Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Passage Bio with a short position of Akero Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Passage Bio and Akero Therapeutics.

Diversification Opportunities for Passage Bio and Akero Therapeutics

-0.42

Correlation Coefficient

Passage Bio  Akero Therapeutics

Very good diversification

The 3 months correlation between Passage and Akero is -0.42. Overlapping area represents the amount of risk that can be diversified away by holding Passage Bio and Akero Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Akero Therapeutics and Passage Bio is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Passage Bio are associated (or correlated) with Akero Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Akero Therapeutics has no effect on the direction of Passage Bio i.e., Passage Bio and Akero Therapeutics go up and down completely randomly.

Pair Corralation between Passage Bio and Akero Therapeutics

Given the investment horizon of 90 days Passage Bio is expected to under-perform the Akero Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Passage Bio is 1.66 times less risky than Akero Therapeutics. The stock trades about -0.13 of its potential returns per unit of risk. The Akero Therapeutics is currently generating about 0.09 of returns per unit of risk over similar time horizon. If you would invest  3,210  in Akero Therapeutics on November 29, 2024 and sell it today you would earn a total of  1,565  from holding Akero Therapeutics or generate 48.75% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Passage Bio  vs.  Akero Therapeutics

Passage Bio

Risk-Adjusted Performance

Very Weak

Over the last 90 days Passage Bio has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain nearly stable which may send shares a bit higher in March 2025. The current disturbance may also be a sign of long-run up-swing for the company stockholders.

Akero Therapeutics

Risk-Adjusted Performance

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Akero Therapeutics are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of very unfluctuating basic indicators, Akero Therapeutics displayed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Passage Bio and Akero Therapeutics

The main advantage of trading using opposite Passage Bio and Akero Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Passage Bio position performs unexpectedly, Akero Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Akero Therapeutics will offset losses from the drop in Akero Therapeutics' long position.

The idea behind Passage Bio and Akero Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.